Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology
Iacovos N. Michaelides, Gavin W. Collie
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3173-3194
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

CD28 co-stimulation: novel insights and applications in cancer immunotherapy
Michael T. Lotze, Scott H. Olejniczak, Dimitris Skokos
Nature reviews. Immunology (2024) Vol. 24, Iss. 12, pp. 878-895
Closed Access | Times Cited: 12
The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation
Tomasz Sobierajski, Joanna Małolepsza, Marta Pichlak, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104032-104032
Open Access | Times Cited: 9
Molecular glue degraders: exciting opportunities for novel drug discovery
Thomas Lemaître, Marie Cornu, Florian Schwalen, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 433-449
Closed Access | Times Cited: 8
Identification of novel 7-hydroxycoumarin derivatives as ELOC binders with potential to modulate CRL2 complex formation
Y. Kim, Seung Jae Baek, Eun-Kyung Yoon, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 17
Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes
Jonathan D. Taylor, Nathalie Barrett, Sergio Martínez Cuesta, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 6
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
USP21-mediated G3BP1 stabilization accelerates proliferation and metastasis of esophageal squamous cell carcinoma via activating Wnt/β-Catenin signaling
Jiazhong Guo, Yunpeng Zhao, Huacong Sui, et al.
Oncogenesis (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
E3 ubiquitin ligases and their therapeutic potential in disease Management
Geet Madhukar, Md Azizul Haque, Shawez Khan, et al.
Biochemical Pharmacology (2025), pp. 116875-116875
Closed Access
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery
Benjamin C. Whitehurst, Matthias R. Bauer, Fredrik Edfeldt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7594-7604
Closed Access | Times Cited: 11
Covalent fragment approaches targeting non-cysteine residues
Noémi Csorba, Péter Ábrányi‐Balogh, György M. Keserü
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 802-816
Open Access | Times Cited: 7
Property-based optimisation of PROTACs
James S. Scott, Iacovos N. Michaelides, Markus Schade
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Drug Discovery Approaches to Target E3 Ligases
A. Rodríguez-Gimeno, Carles Galdeano
ChemBioChem (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 2
A perspective on the changing landscape of HTS
Alice Lanne, Laura Usselmann, Poppy Llowarch, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103670-103670
Closed Access | Times Cited: 6
Review of the impact of fragment-based drug design on PROTAC degrader discovery
Peiqi Chen, Qiang Li, Xiaoguang Lei
TrAC Trends in Analytical Chemistry (2024) Vol. 171, pp. 117539-117539
Closed Access | Times Cited: 1
Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117584-117584
Open Access | Times Cited: 1
N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances
Suddhasatwa Banerjee, Sachin Sharma, Amandeep Thakur, et al.
Current Drug Targets (2023) Vol. 24, Iss. 15, pp. 1184-1208
Closed Access | Times Cited: 3
A Pro‐Fluorescent Ubiquitin‐Based Probe to Monitor Cysteine‐Based E3 Ligase Activity
David A. Pérez Berrocal, T. M. Vishwanatha, Daniel Horn‐Ghetko, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 32
Open Access | Times Cited: 2
Fragment-based approaches to discover ligands for tumor-specific E3 ligases
Junhyeong Yim, S S Kim, Hyung Ho Lee, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-14
Closed Access
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Akash Vikal, Rashmi Maurya, Brij Bihari Patel, et al.
Drug Delivery and Translational Research (2024)
Closed Access
Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs
Jie Huang, Xuekun Fu, Fang Qiu, et al.
Journal of the American Chemical Society (2024)
Closed Access
Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches
Qi Miao, Vilas D. Kadam, Ayan Mukherjee, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 19, pp. 13369-13383
Closed Access | Times Cited: 1
FBDD & De Novo Drug Design
Anwesha Das, Arijit Nandi, Vijeta Kumari, et al.
BENTHAM SCIENCE PUBLISHERS eBooks (2023), pp. 159-201
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top